دورية أكاديمية
أعرض في EDS

Development of 3D-Bioprinted Colitis-Mimicking Model to Assess Epithelial Barrier Function Using Albumin Nano-Encapsulated Anti-Inflammatory Drugs.

التفاصيل البيبلوغرافية
العنوان: Development of 3D-Bioprinted Colitis-Mimicking Model to Assess Epithelial Barrier Function Using Albumin Nano-Encapsulated Anti-Inflammatory Drugs.
المؤلفون: Almutary AG; Department of Medical Biotechnology, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia., Alnuqaydan AM; Department of Medical Biotechnology, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia., Almatroodi SA; Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia., Bakshi HA; The Hormel institute, Medical research Center, University of Minnesota, Austin, MN 55912, USA., Chellappan DK; Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia., Tambuwala MM; Lincoln Medical School, University of Lincoln, Brayford Pool Campus, Lincoln LN6 7TS, UK.
المصدر: Biomimetics (Basel, Switzerland) [Biomimetics (Basel)] 2023 Jan 18; Vol. 8 (1). Date of Electronic Publication: 2023 Jan 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101719189 Publication Model: Electronic Cited Medium: Internet ISSN: 2313-7673 (Electronic) Linking ISSN: 23137673 NLM ISO Abbreviation: Biomimetics (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2016]-
مستخلص: Physiological barrier function is very difficult to replicate in vitro. This situation leads to poor prediction of candidate drugs in the drug development process due to the lack of preclinical modelling for intestinal function. By using 3D bioprinting, we generated a colitis-like condition model that can evaluate the barrier function of albumin nanoencapsulated anti-inflammatory drugs. Histological characterization demonstrated the manifestation of the disease in 3D-bioprinted Caco-2 and HT-29 constructs. A comparison of proliferation rates in 2D monolayer and 3D-bioprinted models was also carried out. This model is compatible with currently available preclinical assays and can be implemented as an effective tool for efficacy and toxicity prediction in drug development.
References: Bioanalysis. 2016 May;8(9):921-37. (PMID: 27071838)
Am J Physiol Gastrointest Liver Physiol. 2001 Oct;281(4):G1092-100. (PMID: 11557530)
Drug Metab Dispos. 2006 Nov;34(11):1893-902. (PMID: 16914511)
Nat Biomed Eng. 2022 Apr;6(4):351-371. (PMID: 35478225)
Toxicol Sci. 2013 Feb;131(2):654-67. (PMID: 23091168)
PLoS One. 2017 Nov 29;12(11):e0187880. (PMID: 29186150)
Lab Chip. 2012 Jun 21;12(12):2165-74. (PMID: 22434367)
Inflamm Bowel Dis. 2012 Dec;18(12):2342-56. (PMID: 22467146)
Pharm Res. 2008 Nov;25(11):2601-12. (PMID: 18654741)
Exp Cell Res. 2013 Jan 1;319(1):75-87. (PMID: 23022396)
Drug Metab Dispos. 2014 Nov;42(11):1947-54. (PMID: 25200868)
Chem Rev. 2020 Oct 14;120(19):10608-10661. (PMID: 32786425)
PLoS One. 2013 Oct 23;8(10):e77232. (PMID: 24194875)
Drug Metab Dispos. 1996 Jun;24(6):634-42. (PMID: 8781778)
Clin Pharmacokinet. 2016 Jun;55(6):673-96. (PMID: 26895020)
Expert Opin Drug Metab Toxicol. 2013 Oct;9(10):1241-54. (PMID: 23687990)
Mol Oncol. 2007 Jun;1(1):84-96. (PMID: 18516279)
Pharm Res. 1993 Nov;10(11):1620-6. (PMID: 8290475)
Drug Metab Dispos. 2016 Mar;44(3):329-35. (PMID: 26700954)
Mucosal Immunol. 2014 Jan;7(1):6-19. (PMID: 24084775)
J Pharm Sci. 2016 Feb;105(2):915-924. (PMID: 26869436)
Minerva Gastroenterol Dietol. 2010 Jun;56(2):233-43. (PMID: 20485259)
Nat Cell Biol. 2016 Mar;18(3):246-54. (PMID: 26911908)
Biomaterials. 2010 May;31(14):3920-9. (PMID: 20185172)
PLoS One. 2016 Jul 07;11(7):e0158674. (PMID: 27387377)
Gastroenterology. 2011 Nov;141(5):1762-72. (PMID: 21889923)
Front Physiol. 2017 Mar 08;8:123. (PMID: 28337147)
J Pharmacol Exp Ther. 1997 Dec;283(3):1552-62. (PMID: 9400033)
Eur J Pharm Sci. 2014 Jun 16;57:280-91. (PMID: 23988844)
Int J Biochem Cell Biol. 2011 Apr;43(4):622-31. (PMID: 21216302)
AAPS J. 2016 May;18(3):589-604. (PMID: 26964996)
PLoS One. 2013;8(3):e59689. (PMID: 23555746)
World J Gastroenterol. 2015 Nov 7;21(41):11793-803. (PMID: 26557003)
Nat Biotechnol. 2014 Aug;32(8):760-72. (PMID: 25093883)
PLoS One. 2012;7(10):e48024. (PMID: 23110163)
J Transl Med. 2012 Mar 06;10:38. (PMID: 22394685)
J Lab Autom. 2015 Apr;20(2):107-26. (PMID: 25586998)
PLoS One. 2010 May 03;5(5):e10431. (PMID: 20454659)
Front Pharmacol. 2013 Jul 08;4:79. (PMID: 23847534)
معلومات مُعتمدة: 10166-cams1-2020-1-3-1 Qassim University
فهرسة مساهمة: Keywords: 3D bioprinting; CAPE; Roxadustat; albumin nanoparticles; barrier function; colitis 3D model; drug prediction
تواريخ الأحداث: Date Created: 20230222 Latest Revision: 20230224
رمز التحديث: 20230224
مُعرف محوري في PubMed: PMC9944493
DOI: 10.3390/biomimetics8010041
PMID: 36810372
قاعدة البيانات: MEDLINE
الوصف
تدمد:2313-7673
DOI:10.3390/biomimetics8010041